NYSE:TEVA 26 January 2026

Teva CEO’s $14.3 Million Tax-Linked Share Sale Lands as Piper Turns More Bullish
····

Teva CEO’s $14.3 Million Tax-Linked Share Sale Lands as Piper Turns More Bullish

Teva CEO Richard Francis sold 442,935 shares for about $14.3 million to cover tax withholding on vested stock awards, a U.S. filing showed. Piper Sandler raised its price target on Teva to $41 after meeting management and kept an overweight rating. Teva is seeking to offset over $1 billion in expected 2026 generic Revlimid sales erosion with branded drugs and a Blackstone-backed bowel disease program.
March 6, 2026
Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions
········

Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions

Novartis said AI reduced trial site selection for a 14,000-person Leqvio study to a two-hour meeting. Drugmakers report AI is cutting weeks from clinical trial logistics and regulatory paperwork. AstraZeneca and others still face challenges managing thousands of regulatory documents. Analysts say it may take one to three years before investors see the full impact on drug development timelines.
January 26, 2026